PDI - Resultado de Búsqueda

Felipe Andres Reyes Cosmelli

Oncólogo Médico

Fundación Aturo López Pérez

Santiago, Chile

Trabajo como investigador principal y sub investigador en múltiples estudios clínicos fases II y III con preferencia en cáncer de pulmón, melanoma, gástrico y urotelial

Medico Internista, UNIVERSIDAD DE VALPARAISO. Chile, 2016
Oncólogo Médico, UNIVERSIDAD DEL DESARROLLO. Chile, 2016
Medico-Cirujano, PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE. Chile, 2010

Médico Other

UNIVERSIDAD DEL DESARROLLO

MEDICINA

Santiago, Chile

2016 - At present

Médico Part Time

Hospital DIPRECA

Santiago, Chile

2011 - 2018
Oncólogo Médico Part Time

Instituto nacional del Cáncer

Santiago, Chile

2014 - 2020
Oncólogo Médico Full Time

Fundació´n Arturo López Pérez

Santiago, Chile

2016 - At present


KEYLYNK-009: Pembrolizumab plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer after Clinical Benefit from First-Line Pembrolizumab plus Chemotherapy Rugo H.S.; Cescon D.W.; Robson ME; Im SA; Dalenc F.; Yanez Ruiz E.; Reyes-Cosmelli, Felipe; Walshe JM; Im YH; Kulyk S; et al. Article CLINICAL CANCER RESEARCH (2026)
Clinical and financial impact of implementation of Oncotype Dx in women with HR positive HER2 negative early breast cancer treated in a Chilean Cancer Center Allende, Roxana; Saffie, Isabel; Canals, Maria; Gonzalez, Catalina; Reyes, Felipe; Torres, Francisca; Saez, Nelson; Vera, Macarena; Chahuan, Badir; Selman, Carolina; et al. Article ISI CLINICAL CANCER RESEARCH (2025)
Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study Shitara K.; Lorenzen, S; Li, J.; Bai, YX; Fernández, MG; Aguilar M.; Shoji H.; Reyes-Cosmelli F.; Peña, YR; Corrales L.; et al. Article ISI SCOPUS Journal of Clinical Oncology (2025)
Genetic Polymorphisms and Tumoral Mutational Profiles over Survival in Advanced Colorectal Cancer Patients: An Exploratory Study Colombo, Alicia; Reyes, Felipe Article ISI SCOPUS Current Oncology (2024)
Pembrolizumab for advanced urothelial carcinoma: exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trial Powles T.; Chang Y.H.; Yamamoto Y.; Munoz J.; Reyes-Cosmelli F.; Peer A.; Cohen G.; Yu E.Y.; Lorch A.; Bavle A.; et al. Article ISI SCOPUS Nature Medicine (2024)
SGLT2 inhibition improves PI3Kα inhibitor-induced hyperglycemia: findings from preclinical animal models and from patients in the BYLieve and SOLAR-1 trials Borrego, MR; Lu, YS; Reyes-Cosmelli F.; Park Y.H.; Yamashita T.; Chiu, J; Airoldi, M; Turner, N; Fein L.; Ghaznawi, F; et al. Article ISI SCOPUS Breast Cancer Research and Treatment (2024)
Dabrafenib plus trametinib versus nivolumab for advanced melanoma Lahoz D.; Reyes F.; Quirland, C Article ISI SCOPUS Medwave (2023)
First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations Paz-Ares; L.G.; Ciuleanu; T.-E.; Cobo; M.; Bennouna; J.; Schenker; M.; Cheng; Y.; BenedÃ©; O.; Mizutani; H.; Lingua; A.; Reyes-Cosmelli; et al. Article ISI SCOPUS Journal of Thoracic Oncology (2023)
Predictors of pathologic complete response to neoadjuvant treatment in HER2-overexpressing breast cancer: a retrospective analysis using real-world data Buscaglia Fernandez, Felipe; Reyes Cosmelli, Felipe; Lagos Chavez, Rodrigo Article ISI SCOPUS ecancermedicalscience (2022)
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update Reck M.; Ciuleanu T.E.; Cobo M.; Schenker M.; Zurawski B.; Menezes J.; Richardet E.; Bennouna J.; Felip E.; Juan-Vidal O.; et al. Article SCOPUS ESMO Open (2021)
Perioperative chemotherapy in locally advanced gastric cancer in Chile: From evidence to daily practice MÃƒÂ¼ller B.; GarcÃƒÂa C.; Sola J.A.; Fernandez W.; Werner P.; Cerda M.; Slater J.; Benavides, C.; Arancibia J.; Ascui R.; et al. Article SCOPUS ecancermedicalscience (2021)
Total neoadjuvant chemotherapy with FLOT scheme in resectable adenocarcinoma of the gastro-oesophageal junction or gastric adenocarcinoma: Impact on pathological complete response and safety Villanueva L.; Anabalon J.; Butte J.M.; Salman P.; Panay S.; Milla E.; Gallardo C.; Hoefler S.; Charles R.; Reyes F.; et al. Article ISI SCOPUS ecancermedicalscience (2020)
Complete preoperative chemotherapy regimen FLOT: Evaluating the safety and histopathologic results in gastric cancer (GC). Villanueva, Luis; Gallardo, Carlos; Reyes, Felipe; Charles, Roberto; Enrique Panay, Sergio; Alejandra Munoz, Maria Article ISI JOURNAL OF CLINICAL ONCOLOGY (2018)
Estatinas: ¿Eficaces en la prevención secundaria de Accidente Cerebrovascular isquémico? DONOSO, JAVIERA; Reyes, Felipe Article ISSN 0718-7203 Revista Memoriza.com 2013 (2009)


Phase 1 study of the anti-immunoglobulin-like transcript 3 (ILT3) monoclonal antibody (mAb) MK-0482+pembrolizumab (pembro) plus paclitaxel for previously untreated advanced triple negative breast cancer (TNBC). Rojas C.; Victoria, I; Ahn J.H.; Park, JJ; Reyes F.; Curigliano G.; Edmondson M.; Myer, N; Bear, AS; Chen M.; et al. Abstract ISI SCOPUS Journal of Clinical Oncology (2025)
Quantitative circulating tumor DNA (ctDNA) assessment in patients (pts) with advanced urothelial carcinoma (UC) treated with pembrolizumab (pembro) or platinum-based chemotherapy (chemo) from the phase 3 KEYNOTE-361 trial Powles T.; Chang W.Y.H.; Yamamoto Y.; Munoz-Langa, J; Reyes F.; Peer A.; Yu E.Y.; Cohen G.; Lorch A.; Bavle A.; et al. Abstract ISI JOURNAL OF CLINICAL ONCOLOGY (2024)
First-Line Nivolumab plus Ipilimumab plus Chemotherapy in Metastatic NSCLC: CheckMate 9LA 3-Year Update Carbone D.P.; Paz-Ares L.G.; Ciuleanu T.E.; Cobo-Dols, M; Bennouna J.; Cheng Y.; Mizutani, H; Lingua A.; Reyes F.; Reinmuth N.; et al. Abstract ISI JOURNAL OF THORACIC ONCOLOGY (2023)
First-line (1L) nivolumab (NIVO) plus ipilimumab (IPI)+2 cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients (pts) with metastatic non-small cell lung cancer (NSCLC): 3-year update from CheckMate 9LA. Paz-Ares L.G.; Ciuleanu T.E.; Cobo-Dols, M; Bennouna J.; Cheng Y.; Mizutani, H; Lingua A.; Reyes F.; Reinmuth N.; de Menezes J.J.; et al. Abstract ISI (2022)
First-line (1L) nivolumab (NIVO) plus ipilimumab (IPI)+2 cycles of chemotherapy (chemo) vs chemo alone (4 cycles) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC): 3-year update from CheckMate 9LA Reinmuth N.; Paz-Ares L.; Ciuleanu T.E.; Cobo-Dols, M; Bennouna J.; Cheng Y.; Mizutani, H; Lingua A.; Reyes F.; Menezes J.; et al. Abstract ISI (2022)
First-line Therapy with Nivolumab (NIVO) plus Ipilimumab (IPI)+2 Cycles of Chemotherapy (chemo) vs Chemotherapy alone (4 Cycles) in Patients (pts) with metastatic non-small cell Lung Cancer (mNSCLC): 3-year Update of CheckMate 9LA Misch, D; Paz-Ares L.G.; Ciuleanu T.E.; Cobo-Dols, M; Bennouna J.; Cheng Y.; Mizutani, H; Lingua A.; Reyes F.; Reinmuth N.; et al. Abstract ISI (2022)


First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update (vol 6, 100273, 2021) Reck M.; Ciuleanu T.E.; Cobo M.; Schenker M.; Zurawski B.; Menezes J.; Richardet E.; Bennouna J.; Felip E.; Juan-Vidal O.; et al. Errata ISI SCOPUS ESMO Open (2021)


The Armed Conflict and the Impact on Patients With Cancer in Ukraine: Urgent Considerations Rolfo, Christian; Gil-Bazo, Ignacio; Cardona, Andres; Hirsch, Fred R.; Gandara, David R.; Morgan, Gilberto; Novello, Silvia; Garassino, Marina-Chiara; Mountzios, Giannis; Leighl, Natasha B.; et al. Review ISI SCOPUS JCO Global Oncology (2022)

1

Francisco Aboitiz

Profesor

Psychiatry

PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE

santiago, Chile

1

Luis Quinones

PROFESOR TITULAR

ONCOLOGIA BASICO-CLINICA

UNIVERSIDAD DE CHILE

Santiago, Chile

1

Alicia Colombo

Profesora Asociada/Director Científico Biobanco de Tejidos y Fluidos de la Universidad de Chile

Departamento de Anatomía Patológica

Universidad de Chile

Santiago, Chile

1

DANTE CACERES

Académico

Programa de Salud Ambiental

ESCUELA DE SALUD PUBLICA, FACULTAD DE MEDICINA, UNIVERSIDAD DE CHILE

SANTIAGO, Chile

1

Nelson Varela

Académico

Oncología Básico-Clínico

UNIVERSIDAD DE CHILE

Santiago, Chile

2

Jorge Sapunar

Head of Unit

Investigación del Cáncer

Instituto Oncológico Fundación Arturo López Pérez

Santiago, Chile

22

Felipe Reyes

Oncólogo Médico

Oncología Médica

Fundación Aturo López Pérez

Santiago, Chile

1

Olga Barajas

PROF. ASOCIADA/MEDICO ONCOLOGO

MEDICINA

HOSPITAL CLINICO UNIVERSIDAD DE CHILE

Santiago, Chile

1

Christian Caglevic

Director Científico

Departamento de Investigación del Cáncer

Fundación Arturo Lopez Perez

Santiago, Chile

1

Sergio Portiño

1

Carlos Gallardo

JEFE TECNICO

INVESTIGACION DEL CANCER

CLINICA ONCOLOGIA FUNDACION ARTURO LOPEZ PEREZ

SANTIAGO, Chile

2

Pamela Salman

Full Professor

Facultad de Medicina y Ciencias de la Salud

Universidad Mayor de Chile

Santiago, Chile

2

Roberto Charles

Cirujano Digestivo

Cirugía

Fundación Arturo López Pérez

Santiago, Chile

2

Luis Villanueva

1

SEBASTIAN HOEFLER

Jefe de Equipo

Cirugia

Instituto Oncologico FALP

Santiago, Chile